tm2620167-5_424b3 - none

424B3 1 tm2620167-5_424b3.htm 424B3 tm2620167-5_424b3 - none - 2.9219066s

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-297528

PROSPECTUS

[MISSING IMAGE: lg_avalotherapeitocs-bw.jpg]

Up to 128,189 Shares of Common Stock Offered by Selling Stockholders

This prospectus relates to the sale or other disposition from time to time of up to 128,189 shares of our common stock, $0.001 par value per share, all held by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successors. We are not selling any shares of common stock under this prospectus and will not receive any of the proceeds from the sale of such securities by the selling stockholders.

The shares of common stock were issued to the certain former stockholders of AlmataBio, Inc. (“AlmataBio”) in connection with that certain Milestone Buyout Option Agreement and Amendment to the Agreement and Plan of Merger and Reorganization, dated as of April 26, 2026, by and among us and the securityholders’ representative, solely in his capacity as the representative agent and attorney-in-fact of former stockholders of AlmataBio (the “Milestone Buyout Amendment Agreement”).

The selling stockholders may sell or otherwise dispose of the common stock covered by this prospectus in a number of different ways and at varying prices derived from the prevailing market price of our common stock at the time of any such sale. We provide more information about how the selling stockholders may sell or otherwise dispose of their securities in the section entitled “Plan of Distribution” beginning on page 13. The selling stockholders will pay all brokerage fees and commissions and similar expenses. We will pay all expenses (except brokerage fees and commissions and similar expenses) relating to the registration of the securities with the Securities and Exchange Commission. No underwriter or other person has been engaged to facilitate the sale of the securities in this offering.

Our common stock is traded on The Nasdaq Capital Market under the symbol “AVTX.” On July 27, 2026, the last reported sale price of our common stock was $19.50 per share. We recommend that you obtain current market quotations for our common stock prior to making an investment decision.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 7 of this prospectus and in the documents incorporated by reference herein, to read about factors you should consider before investing in our securities.

We are a “smaller reporting company” under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and for future filings. See “Prospectus Summary — Implications of Being a Smaller Reporting Company.”

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

Prospectus dated July 28, 2026

	Page
ABOUT THIS PROSPECTUS		1
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS		2
PROSPECTUS SUMMARY		4
THE OFFERING		6
RISK FACTORS		7
USE OF PROCEEDS		10
SELLING STOCKHOLDERS		11
PLAN OF DISTRIBUTION		13
DESCRIPTION OF SECURITIES TO BE REGISTERED		16
LEGAL MATTERS		17
EXPERTS		17
WHERE YOU CAN FIND MORE INFORMATION		17
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE		17

Name	Number of shares of common stock beneficially owned prior to offering		Number of shares of common stock registered for sale hereby		Number of shares of common stock beneficially owned after offering		Percentage of common stock beneficially owned after offering
Boothbay Absolute Return Strategies, LP(1)		18,071		4,379		13,692		*
Boothbay Diversified Alpha Master Fund, LP(2)		6,873		2,301		4,572		*
Emerald Bioventures, LLC(3)		43,576		43,576		—		*
Emily Nixon(4)		301		301		—		*
Ikarian Healthcare Master Fund, LP(5)		65,239		28,180		37,059		*
Justin DiMartino(6)		16,035		15,519		516		*
Mellisa Huhn(7)		9,641		478		9,163		*
Naveen Daryani(8)		377		377		—		*
Navneet Kumar(9)		452		452		—		*
Patrick J. Crutcher(10)		27,239		27,239		—		*
Tatyana Touzova(11)		5,387		5,387		—		*